Indian pharmaceutical industry expansion

Indian pharmaceutical companies are pursuing growth through manufacturing expansion and strategic acquisitions. Micro Labs Limited, a Bengaluru-based firm, continues its operations with a presence in over 50 countries and 17 manufacturing units.

Laurus Labs is focusing on increasing its finished-dose medicines and contract manufacturing sectors. The company reported a 23% year-on-year revenue increase for FY26 and is expanding manufacturing capabilities in Visakhapatnam and Hyderabad, specifically targeting microbial fermentation, gene therapy, and antibody-drug conjugates. To bolster these capabilities, Laurus Labs entered agreements to acquire a 60 per cent stake in Canada-based Galenvs Science and a 52 per cent stake in Hyderabad-based SI&C Resins. The Galenvs Science acquisition is intended to expand access to custom oligonucleotide synthesis and functional magnetic nanoparticle technologies for the North American market.

Additionally, Nucelion Therapeutics, a subsidiary of Bharat Biotech, has partnered with Pandorum Technologies. This collaboration aims to advance investigational therapies for eye diseases by providing manufacturing support for designer exosome-based regenerative medicines.